• Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality
• Sandoz seeks approval in the same indication as the reference medicine, to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy, some of the most serious side effects of cancer chemotherapy[1]
• Sandoz is the global leader in biosimilars and continues to improve patient access and support sustainable healthcare with seven …

• Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc.
   
• Agreement comprises the Sandoz US generic oral solids and Sandoz US dermatology businesses with approximately 300 products and H1 2018 sales of USD 0.6 billion
   
• Transaction supports the Sandoz strategy of focusing on complex generics, value-added medicines and biosimilars to achieve sustainable and profitable growth in the US

Basel, September 6, 2018 – Novartis …